Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Evogene (Nasdaq/TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery announced a joint initiative to accelerate AI-driven small-molecule drug discovery. The program will use Evogene’s ChemPass AI™ generative engine and BCDD experimental infrastructure in an integrated Design-Make-Test-Analyze workflow to support selected academic and entrepreneurial projects.
How this was made
The 30-second read
Why it matters
The initiative centers on an integrated Design-Make-Test-Analyze workflow combining Evogene’s ChemPass AI generative engine with BCDD’s experimental validation and translational support, aiming to reduce early-stage development risk.
Market read
This is a strategic partnership announcement that may support EVGN’s AI drug-discovery positioning, but it lacks disclosed financial terms or near-term milestones.
What to watch
Traders should watch for later disclosures: number of selected programs, any funded budgets, IP/licensing terms via Ramot, and whether ChemPass AI performance is validated with specific candidate outcomes.
Background
Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) are launching a joint initiative to accelerate AI-driven small-molecule discovery from academic and entrepreneurial targets.
Ticker impact
Evogene announced a joint initiative with Tel Aviv University’s Blavatnik Center to use its ChemPass AI for DMTA small-molecule discovery and experimental validation.
Likely modest, sentiment-driven reaction with limited follow-through unless the company later discloses funded programs, milestones, or material commercial outcomes.
The press release is partnership-focused and describes an integrated workflow (DMTA) and access to infrastructure, but provides no quantitative commitments, timelines, or contract economics.
Market effects
Supports the broader AI-small-molecule drug discovery theme by highlighting translational infrastructure access as a differentiator.
Reinforces Israel’s translational research and tech-transfer ecosystem as a pipeline source.
May marginally improve investor perception of AI chemistry platforms’ ability to bridge design and experimental validation.
Counterpoint
Without disclosed funding, exclusivity, or milestone-based economics, the collaboration may be more promotional than value-accretive in the near term.
Key entities
- companyEvogene Ltd.
NASDAQ/TASE-listed computational chemistry company behind ChemPass AI generative engine for small-molecule design.
- research_institutionBlavatnik Center for Drug Discovery (BCDD)
Tel Aviv University translational drug discovery center providing experimental infrastructure and screening capabilities.
- tech_transferTel Aviv University (Ramot)
Tech transfer company managing Tel Aviv University IP and startup collaborations.
